Cassava Sciences Inc. (NASDAQ: SAVA) is 12.61% higher on its value in year-to-date trading and has touched a low of $1.63 and a high of $12.68 in the current 52-week trading range. The SAVA stock was last observed hovering at around $7.09 in the last trading session, with the day’s gains setting it 0.59% off its average median price target of $20.00 for the next 12 months. It is also 68.0% off the consensus price target high of $24.00 offered by 3 analysts, but current levels are 45.14% higher than the price target low of $14.00 for the same period.
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
Currently trading at $7.68, the stock is 0.75% and -7.26% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.62 million and changing 8.32% at the moment leaves the stock 29.53% off its SMA200. SAVA registered -11.01% loss for a year compared to 6-month gain of 146.15%. The firm has a 50-day simple moving average (SMA 50) of $7.60 and a 200-day simple moving average (SMA200) of $6.50.
The stock witnessed a 2.54% loss in the last 1 month and extending the period to 3 months gives it a -33.62%, and is 7.11% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.48% over the week and 6.24% over the month.
Fwd P/E is 48.00. Distance from 52-week low is 371.17% and -39.43% from its 52-week high.
Cassava Sciences Inc. (SAVA) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Cassava Sciences Inc. (SAVA) is a “Buy”. 3 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Cassava Sciences Inc. is expected to release its quarterly report on 05/12/2021 and quarterly earnings per share for the current quarter are estimated at -$0.06.The EPS is expected to grow by 56.70% this year.
Cassava Sciences Inc. (SAVA) Top Institutional Holders
95 institutions hold shares in Cassava Sciences Inc. (SAVA), with 2.1M shares held by insiders accounting for 8.20% while institutional investors hold 28.88% of the company’s shares. The shares outstanding are 24.97M, and float is at 22.20M with Short Float at 23.44%. Institutions hold 26.51% of the Float.
The top institutional shareholder in the company is Blackrock Inc. with over 1.45 million shares valued at $16.64 million. The investor’s holdings represent 5.65% of the SAVA Shares outstanding. As of Sep 29, 2020, the second largest holder is Vanguard Group, Inc. (The) with 1.27 million shares valued at $14.66 million to account for 4.98% of the shares outstanding. The other top investors are Bleichroeder LP which holds 0.68 million shares representing 2.68% and valued at over $7.88 million, while State Street Corporation holds 1.38% of the shares totaling 0.35 million with a market value of $4.06 million.
Cassava Sciences Inc. (SAVA) Insider Activity
The most recent transaction is an insider purchase by BARBIER REMI, the company’s President and CEO. SEC filings show that BARBIER REMI bought 10,000 shares of the company’s common stock on Sep 24 at a price of $9.59 per share for a total of $95900.0. Following the purchase, the insider now owns 1.08 million shares.
Cassava Sciences Inc. disclosed in a document filed with the SEC on Sep 18 that ROBERTSON SANFORD (Director) bought a total of 36,281 shares of the company’s common stock. The trade occurred on Sep 18 and was made at $8.92 per share for $0.32 million. Following the transaction, the insider now directly holds 0.91 million shares of the SAVA stock.
Still, SEC filings show that on Sep 17, Schoen Eric (Chief Financial Officer) acquired 2,000 shares at an average price of $7.04 for $14080.0. The insider now directly holds 27,300 shares of Cassava Sciences Inc. (SAVA).